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Abstract 
The parent compound florfenicol (FF) is a broad spectrum antibacterial compound licensed in 
the UK for use in cattle, pigs and the aquaculture industry.  The analysis of porcine tissues in 
this study demonstrates that significant amounts of solvent non-extractable FF related 
residues are present in incurred tissues (kidney and muscle) from treated animals.   The 
results indicate that methods based on solvent extraction alone carry a high risk of reporting 
false negative results.  The use of a strong acid hydrolysis step prior to solvent extraction of 
tissue samples is necessary for an accurate estimate of the total tissue florfenicol content.  A 
robust and sensitive method for the determination of total florfenicol residue content in kidney 
samples by ultra performance liquid chromatography-tandem mass spectrometry (UPLC-
MS/MS) has been developed and validated.  This method covers the synthetic amphenicol 
drug florfenicol (FF) and its metabolites, measured as the marker residue florfenicol amine 
(FFA) as per Commission Regulation (EU) 37/2010.  Non-extractable and intermediate 
metabolites are converted to the hydrolysis product FFA, and then partitioned into ethyl 
acetate.  Extracts are solvent exchanged prior to a dispersive solid-phase extraction step, 
then analysed using an alkaline reverse phase gradient separation by UPLC-MS/MS.  The 
method was validated around the maximum residue levels (MRLs) set out in commission 
regulation (EU) 37/2010 for bovine kidney in accordance with commission decision 
2002/657/EC.  The following method performance characteristics were assessed during a 
single laboratory validation study:  selectivity, specificity, sensitivity, linearity, matrix effects, 
accuracy and precision (decision limit (CCα) and detection capability (CCβ) has been 
determined). 
Keywords:  florfenicol amine, incurred tissue, non-extractable, kidney, muscle, hydrolysis, 
liquid chromatography, mass spectrometry, UPLC-MS/MS. 
Introduction 
Florfenicol (FF) is a member of the amphenicol antibiotic drug family which includes both 
chloramphenicol (CAP) and thiamphenicol (TAP).  It is a fluorinated analogue of CAP that is 
less likely to cause the blood dyscrasias occasionally found in humans following a dose-
unrelated exposure to that drug. Both FF and TAP lack the p-nitrobenzene component of 
chloramphenicol, thought to be responsible for the idiosyncratic reaction that is seen in 
humans and which led to a prohibition on its use in food-producing animals.(Agency 1996)   
As an important veterinary medicine, FF exhibits a broad antibacterial spectrum of 
activity, higher than TAP and with a higher bioavailability by comparison with the tetracycline 
and quinolone antibiotics in several species.(Park, Lim et al. 2006)  It is effective against both 
gram positive and negative bacteria, exerting its action through the inhibition of protein 
synthesis by deactivation of bacterial ribosome sub-units.  It is marketed under several 
different tradenames (including Nuflor, Resflor and Florocol) for the treatment of a number of 
bacterial infections in aquaculture, livestock and poultry production, including bovine 
respiratory disease (BRD) associated with Pasteurella or Haemophilus bacterial strains, for 
treatment of foot rot associated with Fusobacterium or Bacteroides strains and swine 
respiratory disease (SRD) associated with Actinobacillus, Pasteurella and Bordatella 
infections.  In treated animals, FF is rapidly metabolised to a number of intermediate 
metabolites (mainly florfenicol alcohol, monochloroflorfenicol and florfenicol oxamic acid) 
which are then rapidly converted to florfenicol amine (FFA).  Most of these are excreted via 
the urine, indicating that the kidneys are the major route of clearance.(Jianzhong Liu, Ki-Fai 
Fung et al. 2003)   
FF has MRLs (in all food-producing species) listed in Table I of Commission 
Regulation (EU) No 37/2010.(Commission. 2010)  The MRLs in bovine and porcine kidney 
are 300μg/kg and 500μg/kg, respectively, with the marker residue defined as ‘the sum of 
florfenicol and its metabolites measured as florfenicol amine’.(Agency 1996)  It is not 
permitted for use in animals from which milk or eggs are produced for human consumption.  
In the UK, it is licensed for use in cattle, pigs and salmon, either by injection or via feeding-
stuffs.  
 Several methods have been published for the analysis of FF alone or in 
combination with FFA.  These include several multi-amphenicol methods(Luo, Chen et al. 
2010, Alechaga, Moyano et al. 2012, Rezende, Filho et al. 2012, Zou, Zhao et al. 2013, Tao, 
Zhu et al. 2014, Pan, Wu et al. 2015) and several multi-class antibiotic methods.(Fedorova, 
Nebesky et al. 2014, Rezk, Riad et al. 2015, Schneider, Lehotay et al. 2015)  However, these 
methods rely on the extraction of tissue samples with an organic solvent, followed by a solid-
phase clean-up step, either in a column format or as a dispersive step.  The assumption has 
therefore been made that FF related residues are extractable and mainly present as either FF 
or FFA.  However, metabolism studies using radio-labelled FF have shown that non-
extractable residues are predominant in tissues from numerous species (Schering-Plough 
1996). To account for all FF related residues in tissue it is necessary to include a hydrolysis 
step prior to sample extraction to convert the parent drug and its metabolites to the single 
marker residue FFA.(Wrzesinski, Crouch et al. 2003)  
 Consequently, there are few screening or confirmatory methods in the literature that 
fulfil the MRL definition, and a lack of data on the effect of hydrolysis on incurred residues 
measured in tissue samples.  Methods published by some authors include a strong acid 
hydrolysis step prior to sample extraction to account for all FF related tissue content.  The first 
of these was in channel catfish using HPLC-UV(Wrzesinski, Crouch et al. 2003) and the 
second a confirmatory method in porcine muscle by HILIC LC-MS/MS.(Kong, Deng et al. 
2014)  Although the latter method met the requirements of commission decision 
657/2002(Commission 2002) and provided data relating to the total FF content in incurred 
porcine muscle samples, there remains a lack of data relating to the extractable versus non-
extractable FF related content in incurred tissues. 
 To the best of the author’s knowledge, this is the first UPLC-MS/MS method 
presented for the analysis of total FF residue content in tissue samples. The data presented 
here also demonstrate that between 79 to 96% of FF residues in the incurred tissues studied 
were non-solvent extractable, which is of particular relevance for regulatory laboratories 
world-wide.  The results unequivocally show that the use of a solvent extraction method alone 
cannot be used, and that a whole tissue hydrolysis procedure must be used to meet the 
residue marker definitions set in EU legislation.  It is likely that there is significant under-
reporting of tissue samples which exceed the statutory florfenicol MRL (or equivalent) within 








Reagents and Materials 
Analytical grade reagents and HPLC grade solvents were used throughout.  Methanol was 
obtained from Romil (Cambridge UK).  Acetonitrile, sodium hydroxide (NaOH) pellets, 
ammonium hydroxide solution (35%), concentrated hydrochloric acid (HCl, 12.1N), di-
potassium hydrogen orthophosphate (K2HPO4), Eppendorf tubes (1.5ml) and disposable 
borosilicate glass turbovap tubes (16 x 100mm) from Fischer scientific (Leicestershire, UK).  
Ethyl acetate was obtained from Sigma Aldrich (Dorset, UK).  Grade 1 (18MΏ.cm) water was 
used throughout, obtained from an in house Milli-Q system (Millipore corp., Livingston, UK).  
Endcapped C18 sorbent material (Sepra C18-E, 50μm) from Phenomenex (USA).  Screw 
capped glass centrifuge tubes (50 ml) with Teflon lined caps were used for hydrolysis.  
Analytical standard powders for Florfenicol (purity >99%) and Florfenicol amine (purity 
>99.6%) were obtained from Sigma-Aldrich and Witega (Berlin, Germany) respectively. 
Individual stock solutions of Florfenicol (FF) or Florfenicol amine (FFA) were prepared 
at 1mg/ml in methanol.  Working standards were prepared for FF at 14.45μg/ml (equivalent to 
10μg/ml of FFA, for use during spiked experiments), and FFA at 10 μg/ml by dilution of stock 
aliquots with methanol.  Standards were stored in 25ml amber glass vials at -20ºC for up to 6 
months.  The working standard for FF was used to prepare method matched calibration 
curves (spiked pre-hydrolysis) and for fortification of recovery samples.  A single level solvent 
standard (post hydrolysis and post extraction) was also prepared for FF and FFA from the 
working standards for identification of FF (to ensure complete conversion to FFA). 
 
Preparation of additional reagent solutions 
(a) 6N HCl – Add 50ml of concentrated HCl to 50ml of water and mix carefully.  Prepare daily 
as required. 
(b) 1M K2HPO4 – 17.42grams of di-potassium hydrogen orthophosphate was added to 100ml 
of water and mixed until dissolved. Prepared fresh daily. 
(c) NaOH, 50% (w/w) – Add 50ml of water to a beaker immersed in an ice bath, then add 50 
grams of NaOH pellets carefully, stirring until dissolved with a glass rod.  Transfer to a 100ml 
volumetric cylinder and adjust to 100ml with water. 
(d) 0.5% ammonia in methanol – Add 250µl of 35% ammonia solution to 50ml of methanol in 
a measuring cylinder and mix.  Prepare fresh daily. 
(e) HPLC mobile phase A – 0.05% v/v ammonia in water (pH >10.6) – Add 125µl of 35% 
ammonia solution to 250ml of UPLC grade water.  Check final pH and adjust to above pH10.6 
by adding additional ammonia solution in 25µl aliquots.  Prepare fresh daily. 
(f) HPLC mobile phase B – 100% acetonitrile 
(g) Weak needle wash 20% methanol – add 50ml of methanol to 200ml of water and mix. 
(h) Strong needle wash 90% methanol – mix 225ml of methanol with 25ml of water. 
 
Instrumentation and conditions 
UPLC separations were carried out using a Waters UPLC sample manager and binary 
solvent system.  A reverse phase gradient separation was achieved on a Waters Acquity BEH 
C18 chromatographic column (50 x 2.1mm, 1.7µm) with an in line filter assembly (0.5µm 
porosity) (Waters, Milford, USA).  The sample compartment was set at 10ºC, column 
temperature at 50ºC, and an injection volume of 5µl used.  The mobile phases were (A) 0.5% 
ammonia in water and (B) acetonitrile, with a flow rate of 0.4ml/min.  The flow was diverted to 
waste during sample injection cycles at 0.1-0.9 min and again from 1.85min until the end of 
an injection cycle.  Linear gradient steps were used with initial conditions set at 100% A,  
decreasing to 50% A after 2min, 10%A at 2.5min, held for 0.7min, then returned to 100% A at 
4min. A re-equilibration period of 2min was used.  Total analysis time was 6min per sample.  
 A Waters Premier XE triple-quadrupole was used for mass spectrometric analysis, 
which was connected to the UPLC system via an electrospray ionisation (ESI) interface 
source.   FF was analysed in negative ESI, with FFA analysed in positive ESI mode.  Fast 
polarity switching was not required as sufficient chromatographic separation was achieved.  
The following instrument conditions were used:  source temperature 150ºC, desolvation gas 
450ºC, cone gas flow 80 l/hr, desolvation gas flow 1000 l/hr, capillary voltages were +3kV in 
positive mode and -2.2kV in negative mode.  Nitrogen was used for source, cone and 
desolvation gas, with argon as the collision gas.  For both modes analyser settings were 
optimised for maximum transmission and set at unit mass resolution.  Detection was 
performed in multiple reaction monitoring mode (MRM).  Precursor and product ion transition 
experiments were optimised by infusion of individual standard solutions at 10µl/min using the 
integrated syringe pump into mobile phase via a zero dead volume T-piece.  The MRM 
experiment is summarised in Table 1.  The most intense MRM was used as the quantitative 




All control tissue samples were confirmed to be negative for FF related residues prior to use 
in validation studies.  The method validation study was carried out using bovine kidney.  In 
addition, incurred porcine kidney and muscle samples were obtained from pigs that had 
previously been fed florfenicol medicated feed as part of a withdrawal study.  Samples were 
available from pigs at withdrawal periods of 0, 3, 6, 10, 12 and 14 days.  These were 
analysed for extractable and non-extractable residues, and with the whole tissue hydrolysis 
procedure.  All samples were minced using a laboratory blender and then frozen until needed 
at   -20ºC.  On the day of analysis samples were defrosted at room temperature and mixed 
thoroughly prior to weighing of aliquots. 
 
Sample hydrolysis and extraction 
For the whole tissue hydrolysis procedure, 2 grams of tissue sample was weighed into a 50ml 
screw cap hydrolysis tube.  Selected blank samples for recovery evaluation or matrix 
standard calibrants were fortified at this stage with the FF working standard and allowed 
equilibrate for 10 minutes before proceeding.   
Hydrochloric acid (6N, 4ml) was added to each tube, which was then vortexed for 30 
seconds.  All tubes were capped and incubated in a water bath for 2 hours at 100ºC.  Tubes 
were vortexed intermittently to ensure complete digestion of the tissue sample, removed and 
allowed to cool for 30 minutes. 
The pH of the hydrolysate in each sample tube was then adjusted to above pH 10 by 
adding 5ml of 1M di-potassium hydrogen orthophosphate solution followed by increasing 
amounts of 50% sodium hydroxide (2ml added initially to each tube, and then adjusted drop 
wise using a Pasteur pipette).  To each tube, 5 ml ethyl acetate was then added. The tubes 
were capped and shaken for 30 seconds prior to centrifuging at 2000 rpm for 10 min.  The 
ethyl acetate extract was transferred to a disposable clean 16 ml glass tube.  The ethyl 
acetate extractions were repeated on a further two occasions and then combined for 
individual samples.  All tubes were evaporated to dryness at 50 ± 2 ºC under nitrogen.  To 
each tube, 1ml of 0.5% ammonia in methanol was added, vortex mixed for 1 minute and 
sonicated for 1 minute. To each tube 1ml of water was then added and vortex mixed for 1 
minute. 
Dispersive solid phase extraction (dSPE):  Aliquots of 1ml were transferred to 
Eppendorf tubes containing 150mg of endcapped C18 sorbent, vortex mixed for 1 min and 
then ultra-centrifuged at 13000rpm for 5minutes at room temperature.  Aliquots were then 
transferred to vials for LC-MS/MS analysis. 
 
Method validation 
The validation of the whole tissue hydrolysis method was carried out according to 
Commission Decision 2002/657/EC in bovine kidney tissue on each of three separate days.  
On each day, thirty aliquots of negative bovine kidney were weighed into separate 50ml screw 
cap hydrolysis tubes.  Recovery samples were then spiked at 0.5, 1 or 1.5 times the MRL with 
seven replicates at each level as follows:  30µl, 60µl or 90µl of the 14.45µg/ml FF secondary 
standard (equivalent to 150, 300 or 450 µg kg-1 FFA equivalents) was added to 2g tissue. 
Three negative samples and six matrix calibrants were also prepared on each day.  Matrix 
standards were prepared to cover a linear range from 0-1000 µg kg-1 (FFA equivalents) and 
fortified prior to hydrolysis.  All tubes were then subjected to the whole tissue hydrolysis 
procedure. 
 
Incurred sample studies 
For the incurred residue hydrolysis studies, matrix control samples were prepared as follows: 
Two negative controls, four recovery samples fortified at 0.5 x MRL and six matrix calibrant 
tubes in the range 0-1000 µg kg-1 were prepared for each analysis (as FFA equivalents).  To 
investigate solvent non-extractable versus solvent extractable FF related residues in incurred 
samples the following experiment was designed.  Incurred kidney or muscle samples and 
controls were weighed singly into screw cap hydrolysis tubes. To each tube 2 ml of water and 
12 ml of acetonitrile was added. The samples were homogenised for 1 min, then centrifuged 
at 3500 rpm for 10 minutes at 4ºC.  The extracts were decanted into separate turbovap tubes 
and the tissue pellets retained in the hydrolysis tube. 
The extracts were evaporated to dryness under nitrogen at 50˚C and 2ml of 6N 
hydrochloric acid was then added, vortexed gently and sonicated for 5 minutes. The 
reconstituted extract was transferred to a 50ml hydrolysis tube.  A further 2ml of 6N 
hydrochloric acid was added to each turbovap tube, vortexed and combined with the previous 
fraction.  To the separate tissue pellets 4mls of 6N hydrochloric acid was added and each 
tube vortexed for 30 seconds.  At this stage control sample tubes were spiked for recovery 
assessment and matrix standard calibrant preparation (tissue pellets and extract tubes).   All 
tubes were capped and subjected to the sample hydrolysis/extraction method previously 
described, prior to analysis by LC-MS/MS. 
In addition to the hydrolysis experiments described, the incurred kidney samples were 
analysed by the following summarised procedure to assess the levels of ‘free’ FF or FFA 
present in extracts when using a typical solvent extraction procedure alone.  Tissue samples 
and control samples (2 grams) were weighed into 50ml centrifuge tubes. Samples for 
recovery estimation were fortified with both FF and FFA at 100 µg kg-1.   All samples were 
extracted by homogenisation with 2 ml of water and 12 ml of acetonitrile.  The whole extract 
was then subjected to a dispersive clean-up with 0.5grams of C18 material.  Extracts were 
transferred to turbovap tubes and calibration standards fortified at this stage to cover a linear 
range from 0-100 µg kg-1 (both FF and FFA).  Samples were evaporated and reconstituted to 
a final volume of 2ml with 50% methanol, then analysed by the LC-MS/MS procedure 
described. 
 
Results and discussion  
Optimisation of UPLC conditions 
The chromatographic separation was optimised by assessing various mobile phase 
conditions on a Waters BEH C18 particle UPLC column.  This hybrid particle has a stable pH 
range of 1-12 allowing different pH conditions to be assessed.  FFA is a hydrophilic 
compound with a polar amino group which easily ionises at lower pH values.  It was found 
that increasing the pH of the mobile phase improved retention and peak shape for FFA.  This 
was expected as the amino group would not be fully ionised at higher pH values, resulting in a 
reduced hydrophilic nature.  Figure 1 demonstrates the separation of FFA and FF using the 
final mobile phase and gradient conditions developed.  In the separation used, FFA eluted at 
four times the column void volume (t0) which exceeds the minimum acceptance criteria 
required by Commission Decision 2002/657/EC(Commission 2002) of twice the column void 
volume.  A retention factor (k) of 2.7 for FFA was also calculated which is within the desirable 
range of 1-5 (k= retention time FFA-T0/T0).  Excellent peak shape and retention time stability 
was achieved for both compounds during analyses (FF was monitored to ensure complete 
conversion to FFA during the hydrolysis step).  No interfering peaks were observed close to 
the retention time of either analyte.  The UPLC column was subjected to >3000 routine 
sample injections with no loss in chromatographic performance observed. 
 
Optimisation of hydrolysis and extraction procedure 
Initial optimisation of ethyl acetate extractions was carried out at pH10 and 12.  FFA 
standards were prepared (in triplicate) in a 1M di-potassium hydrogen orthophosphate 
solution.  FFA has a pKa value of 7.5, therefore for an efficient extraction of polar FFA drug 
residues from aqueous extracts into an immiscible organic solvent, a pH adjustment to >9.5 is 
required to ensure >95% of the drug is in its neutral state and amenable to extraction. A 
triplicate extraction with 5ml of ethyl acetate at either pH was sufficient to recover more than 
80% of the added FFA content.  A further 15% was recoverable through an additional 
extraction step when compared with standards prepared post extraction (all experiments were 
carried out in triplicate, data not shown).  Adjustment to at least pH 10 was therefore used in 
the final hydrolysis method. 
 Several parameters were investigated for the hydrolysis procedure, including 
temperature, time, acid strength and the stability of FFA residues in strong acid.  Initial trials 
used 1N or 6N HCl for the hydrolysis of FF solvent standards for 4 hours at 100ºC.  The 
results demonstrated incomplete conversion of FF to FFA when using 1N HCl.  The use of a 
strong acid hydrolysis (6N HCl) step was necessary to convert all FF related residues to the 
marker FFA, as described by other authors.(Wrzesinski, Crouch et al. 2003, Kong, Deng et al. 
2014)  In a further trial to optimise hydrolysis time and temperature, an incurred avian muscle 
sample was used.  A FF solvent standard, tissue blank (for matrix standard), FF tissue 
recovery at 100 µg kg-1 and the incurred sample (mean measured content 95 µg kg-1) were 
prepared at each of the following timepoints: 2, 4, 6 and 8 hours.  These were subjected to 
hydrolysis at temperatures of 70ºC and 100ºC.  Matrix standards were prepared by spiking 
both FF and FFA into the ethyl acetate extracts (post-extraction) prior to the drying and 
reconstitution step.  The complete conversion of FF to FFA was achieved within 2 hours at 
100ºC for the solvent standard, incurred tissue and recovery samples (data not shown).  No 
remaining FF was evident beyond the initial sampling time of 2 hours, and there was no 
significant increase beyond this time-point in FFA concentrations for the incurred sample.  In 
contrast the same experiment at 70ºC failed to achieve complete conversion in the same 
samples, with FF still measurable after 8 hours in the recovery and incurred tissue samples.  
It was also observed that some tissue material remained in the 70ºC hydrolysis tubes for 
several time points indicating incomplete tissue digestion at the lower temperature. 
 
Optimisation of sample clean-up 
The use of a dispersive solid phase extraction step (dSPE) was evaluated for sample clean-
up to reduce sample type related matrix effects.  These can have a significant impact on the 
robustness of a method due to enhancement or suppression of analyte ionisation in the 
electrospray ion source.  Typically sorbents such as C18 or primary secondary amine (PSA), 
alone or in combination are used for dSPE, depending on the matrix.  PSA sorbent is effective 
in removing polar acidic compounds such as free fatty acids(Kong, Deng et al. 2014), 
however it is less effective at removing other non-polar materials.(Rezende, Filho et al. 2012)  
It is not uncommon for a sorbent used in this way to also remove a proportion of the target 
analyte(s) during any dSPE step.  This is usually accepted as a trade off, providing the losses 
are concentration independent.  In this study the use of endcapped and non-endcapped C18 
material was evaluated by preparing mixed FF and FFA solvent standards at 500ng/ml in 50 
to 70% methanol (with 0.5% ammonia).  The results in Table 2 show that the use of 
endcapped C18 material is necessary to prevent significant losses of FFA during the dSPE 
step.  Most losses were attributed to residual acidic silanol groups on the non-endcapped C18 
material interacting with FFA, as little difference was observed for FF.  The inclusion of 
ammonia at 0.5% in the methanol component helped to reduce losses by blocking unwanted 
secondary ionic interactions, and as expected was more effective with the endcapped 
material.  The percent of methanol used for the dSPE also has a significant impact if using a 
non-endcapped material.  In the method presented the final extracts are prepared in 50% 
methanol with ammonia, as increasing the methanol component did not significantly improve 
recovery of FFA when using the endcapped sorbent.  A lower methanol content may also 
reduce potential non-polar interferences. 
 
Stability studies 
FFA proved to be very stable in 6N HCl at 100ºC, the results in Figure 2 demonstrate the 
stability of solvent standards (prepared by spiking with FFA prior to hydrolysis) for up to 8 
hours.  The stability of FFA in extracts was investigated by preparing matrix standards (in 
multiple tissue types) and analysing on the same day against a freshly prepared FFA solvent 
standard.  The extracts were stored for one week at 4ºC, then reanalysed against a freshly 
prepared solvent standard.  The results of the normalised data (against the solvent standard) 
demonstrated that FFA extracts were stable for at least one week in tissue extracts, 
regardless of the matrices evaluated.  Other authors have already demonstrated the stability 
of FFA as solvent standards in a freezer for up to six months(Kong, Deng et al. 2014), or in 




Kidney and muscle extracts for bovine and porcine tissues were prepared by the whole tissue 
hydrolysis procedure described (with and without dSPE).  Matrix effects were then assessed 
by two different approaches against the developed UPLC method.  Firstly, the prepared tissue 
extracts were injected and analysed (as MRM experiments) with post-column infusion of a 
mixed FF/FFA standard.  This was carried out at several different levels (10ng/ml, 100ng/ml, 
250ng/ml and 1000ng/ml in 50% methanol) and compared with a solvent blank injection.  
Secondly, matrix and solvent standards were prepared at 100ng/ml for FF/FFA from these 
extracts by reconstitution of the relevant matrix extract with known standard amounts or with 
methanol.  These were injected without post-column infusion.   
 The results for the infusion experiments did not indicate a difference between 
matrices at any of the standard concentrations used.  No significant baseline difference was 
observed around the retention time of FFA or FF.  However, it was useful in providing 
evidence that the dSPE step did remove significant non-polar sample interferences (usually 
attributed to phospholipids or lipoproteins) as the non-dSPE traces indicated significant 
baseline depression at a much later retention time as shown in Figure 3.  Such co-extractants 
have the potential to cause method robustness issues such as ‘ghost peaks’ during repeated 
injection cycles and can impact on chromatographic peak quality and column lifetime (due to 
a build up of sample material on the head of the column). 
 In contrast, the second approach which compared matrix and solvent standards 
(shown in Table 3), demonstrated that the inclusion of a dSPE step significantly reduced 
matrix related ion suppression effects for both FFA and FF, which could not be observed 
using the post-column infusion experiments.  The matrix effect (ME) was calculated and 
expressed as a %ME as follows: 
 
%ME = (matrix standard peak area –solvent   standard peak area)  x 100 
   solvent std peak area 
 
The results indicate that the matrix effect was still evident after clean-up, and that the use of 
matrix matched standards is required for analyses.  The inclusion of PSA in combination with 
C18 or alone was not investigated as the performance characteristics of the method were 
found to be within acceptable limits (refer to validation results).  In the whole tissue hydrolysis 
method described, recovery and matrix standard samples are fortified prior to the initial 
hydrolysis step.  Hydrolysis efficiency, extraction losses and matrix effects are therefore 
accounted for in the procedure.   
 
Incurred tissue studies and solvent non-extractable residues 
The results for the solvent non-extractable (SNE) study in porcine kidney and muscle are 
presented in Tables 4 and 5 (assessing hydrolysed tissue pellets and hydrolysed extracts 
separately).  The results demonstrate that at zero days withdrawal, >80% of the measurable 
FF content in kidney and >65% in muscle tissues is ‘solvent non-extractable’, with a tendency 
for the proportion of SNE residues to increase with withdrawal time.  This is in agreement with 
the data submitted for the original licence approval of Nuflor which also indicated significant 
non-extractable residues in tissue radioisotope studies.(Schering-Plough 1996)   
 The combined values for extracted and non-extracted FFA content demonstrate 
that the MRL of 500 µg kg-1 in porcine kidney was exceeded for up to 10 days after 
withdrawal. Pig muscle samples did not exceed the MRL of 300 µg kg-1 at any point. The 
results indicate that kidney tissues should be sampled for any residue surveillance 
programme to ensure compliance with EU Regulation 37/2010(Commission. 2010) and to 
ensure that appropriate withdrawal periods are being followed.  The results of 
pharmacokinetic studies of FF have also indicated a major kidney clearance in cattle and 
pigs.(Jianzhong Liu, Ki-Fai Fung et al. 2003)   
 Of particular significance, the results indicate that methods of analysis, which rely 
on a solvent extraction step alone, will have a 100% false negative rate, even at a zero day 
withdrawal period.  This is alarming considering the number of methods published intended to 
cover multiple amphenicol drugs in a single analysis, or indeed multi-residue analyses which 
include FF and occasionally FFA in the analytical suite.  These procedures are validated 
using materials spiked with solvent standards around the MRL, which has lead analysts to 
assume the method is fit for purpose due to sufficient precision and accuracy of fortification 
experiments.  Consequently, there is a possibility of significant under-reporting of ‘non-
compliant’ samples.  The results presented here reinforce the need for the use of incurred 
materials during method development, in particular where non-extractable or bound residues 
need to be taken into account.   
 Further work was carried out to investigate the possibility of recommending a ‘lower 
threshold screening value’ for FF and FFA below the appropriate tissue MRL by using a 
solvent extraction method alone (without a hydrolysis step).  In theory, a result could trigger 
the use of a whole tissue hydrolysis method if FF and FFA were above this ‘threshold’ level in 
tissue.  This would only be possible if FF and FFA in tissue extracts was present at detectable 
levels as ‘free’ residues (not bound to low molecular weight co-extracted material), and if the 
proportions remained constant relative to the whole tissue content over the withdrawal period 
of interest (up to 10 days in the pig kidney samples).  The results for the incurred porcine 
kidney extracts not subjected to hydrolysis are also presented in Table 4.  The levels of ‘free’ 
FF or FFA measured were at trace levels in most samples, with no consistent ratio to the total 
measured hydrolysis content, demonstrating that this approach cannot be recommended. 
 
Validation results 
Selectivity, specificity, sensitivity and linearity 
The selectivity of the method was verified by analysing negative tissue samples with each of 
the validation and incurred sample batches.  Representative MRM chromatograms of blank, 
spiked and incurred tissue samples are shown in Figure 4.  The absence of interfering peaks 
close to the retention time of either analyte in negative bovine or porcine tissue extracts 
demonstrated the selectivity of the analytical method.  The retention time in spiked or incurred 
positive samples corresponded to calibration standards within the ±2.5% tolerance permitted 
for LC methods.  Figure 5 shows the linearity of FFA in hydrolysed extracted standards over 
the calibration range 50-1000 µg kg-1.  All calibration plots exceeded a correlation coefficient 
(R2) of higher than 0.97 for each of the three validation days in bovine kidney (Table 6) and 
the incurred tissue studies (porcine kidney and muscle).   
 The specificity of the method was determined by comparison of the MRM ion ratios 
for FFA in validation spiked controls and incurred tissue samples against matrix standards.  
Two MRMs per analyte are required to fulfil the minimum identification criteria required by 
commission decision 2002/657/EC(Commission 2002), however a third MRM was included 
for FFA.  Ion ratios were calculated as the ratio of each qualifier ion against the quantifier ion 
using Waters Targetlynx quantitation software.  All validation controls and incurred results 
were within the acceptable limits as set in the legislation, and exceeded the 3 identification 
points required (5.5 total points were achieved as one precursor and three product ions were 
monitored).  The ion ratio precision on different days and for different matrices was also 
calculated.  The RSD value of the ratios on each day are lower than the permitted tolerances 
set by 2002/657/EC(Commission 2002) (refer to Table 6), indicating that the selected MRMs 
are sufficiently specific for the identification of FFA. 
 
Accuracy and Precision 
Validation was carried out according to decision 2002/657/EC(Commission 2002) by spiking 
seven replicates for each level to be assessed, at concentrations corresponding to 0.5, 1.0 
and 1.5 times the MRL.  The accuracy and precision of the method was evaluated by 
comparing the recoveries of FFA in spiked bovine kidney samples against the target spiked 
concentration, at different concentrations over three validation days.  The data are presented 
in Table 7.  Accuracy values from 92% to 108% at the MRL were obtained over three days, 
with a mean overall recovery (accuracy) of 100% for FFA over all concentration levels. 
Method precision was estimated at each validation level as follows: Firstly as intra-day 
repeatability, calculated as the relative standard deviation for repeatability (%RSDr) obtained 
within a batch, and as within laboratory repeatability (%RDSR), calculated as the relative 
standard deviation over the three validation days by a single analyst.  Table 8 shows that the 
precision RSDr values ranged from 6.6% to 11% and the RDSR values from 2.9% at the 
1.5xMRL level to 13.7% at the 0.5 MRL level.  For substances with a permitted limit, the 
RDSR values at half the MRL should be less than the predicted Horwitz equation target value 
of 23% for within laboratory reproducibility.(Commission 2002)  The results demonstrate that 
method precision meets the legislative requirements for validation. 
 
Decision limit (CCα) and Detection capability (CCβ) 
The calculated CCα and CCβ values are shown in Table 7.  The values were calculated 
according to decision 2002/657/EC(Commission 2002) by plotting the calculated 
concentration against the added concentration for each of the three days at the validated 
levels of 0.5, 1.0 or 1.5 times the MRL.  For MRL substances, any sample with a confirmed 
concentration greater than the MRL with a statistical certainty of at least 95% (CCα) is non-
compliant with community legislation. An α-error and β-error of 5% was applied based on the 
inter-day RSD data obtained at the MRL.   
 
Conclusions 
The results of the incurred tissue study presented here demonstrate that significant FF related 
residues remain in kidney and muscle samples from FF treated pigs that are solvent non-
extractable (SNE).  A confirmatory UPLC-MS/MS method has been validated in bovine kidney 
that can be used to quantify total FF related content in tissue samples.  Tissue samples which 
are taken as part of a national residue control program must include a whole tissue hydrolysis 
procedure when analysing for FF related content.  If a method for tissue residues, not 
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Table 1:  Tandem mass spectrometry conditions  
 
 
  FFA FF 
%Methanol Endcapped C18 % Recoverable  % Recoverable  
50 Yes 94 91 
50 No 59 90 
60 Yes 95 90 
60 No 72 88 
70 Yes 97 99 
70 No 80 94 
Table 2: Optimisation of the dSPE step. FFA and FF solvent standards prepared in increasing % methanol 
(containing 0.25% ammonia) at 500ng/ml.  1ml of standard subjected to dSPE with 150mg of C18 material. The data 






% ME (without 
dSPE) FFA 
% ME (with 
dSPE) FFA 
% ME (without  
dSPE) FF 
% ME (with 
dSPE) FF 
Porcine Kidney -31.3% -19.8% -37.7% -23.2% 
Bovine Kidney -39.6% -17.8% -36.0% -23.2% 
Porcine Muscle -24.8% -18.9% -43.7% -25.2% 
Bovine Muscle -19.1% -8.6% -27.4% -17.6% 
Table 3: Matrix effect (%) in different matrices with and without the inclusion of a dSPE clean-up step, for FFA and 
FF compared to solvent standard responses (peak area counts).  Standards were prepared by reconstitution of 
known standard amounts with the relevant matrix extract or with 50% methanol (containing 0.25% ammonia).  






     






(µg kg-1 FFA) 
NON-
EXTRACTABLE 
(µg kg-1 FFA) 
COMBINED 








DAY 0 347.8 1292.1 1639.9 78.8 68.6 4 
DAY 0 482.5 1971.9 2454.4 80.3 52.1 37.9 
DAY 0 293.8 1215 1508.8 80.5 49.3 11.4 
DAY 3 81.5 1062 1143.5 92.9 2.4 <2 
DAY 3 97.2 771.7 868.9 88.8 3.9 <2 
DAY 6 151 1081.8 1232.8 87.8 4.8 6.2 
DAY 6 87.8 405.1 492.9 82.2 4.1 2.7 
DAY 10 93.8 310.3 404.1 76.8 2 ND 
DAY 10 75.7 471.3 547 86.2 <2 ND 
DAY 10 50 396.7 446.7 88.8 <2 ND 
DAY 10 39.4 373.7 413.1 90.5 ND ND 
DAY 12 30.6 260.8 291.4 89.5 <2 3 
DAY 12 28.4 259.7 288.1 90.1 <2 <2 
DAY 14 13.5 290.9 304.4 95.6 ND <2 
DAY 14 9.7 235.4 245.1 96.0 ND ND 
Table 4:  Solvent extractable and solvent non-extractable study results (columns 2-5) from incurred porcine kidney 
samples.  Samples were obtained from animals which were fed on Florfenicol medicated feed (at 10mg florfenicol per 
kg body weight per day for five consecutive days) and then subjected to withdrawal periods of 0 to 14 days (Note: the 
recommended withdrawal period for Nuflor is 14 days).  The MRL listed in 37/2010 EC for porcine kidney is 500 µg 
kg-1.  In addition, tissue extracts were analysed using an alternate method (without a hydrolysis step) to determine 
the levels of FF or FFA present as unbound residues in extracts (‘free’ content; columns 6-7).  Recovery of the 


















(µg kg-1 FFA) 
NON-
EXTRACTABLE 
(µg kg-1 FFA) 
COMBINED 




DAY 0 35.05 86.88 121.93 71.3 
DAY 0 55.87 107.07 162.94 65.7 
DAY 0 28.81 57.9 86.71 66.8 
DAY 3 11.03 64.36 75.39 85.4 
DAY 3 11.44 87.63 99.07 88.5 
DAY 6 16.73 92.02 108.75 84.6 
DAY 6 13.53 83.41 96.94 86.0 
DAY 10 12.38 61.77 74.15 83.3 
DAY 10 8.97 52.35 61.32 85.4 
DAY 10 11.24 57.81 69.05 83.7 
DAY 10 14.61 66.37 80.98 82.0 
DAY 12 10.44 34.99 45.43 77.0 
DAY 12 8.75 42.45 51.2 82.9 
DAY 14 10.36 62.86 73.22 85.9 
Table 5:  Solvent extractable and solvent non-extractable study results from incurred porcine muscle samples 
obtained from animals which were fed Florfenicol medicated feed and then subjected to withdrawal periods of 0 to 14 
days.  The MRL listed in 37/2010 EC for porcine muscle is 300 µg kg-1 
 
 
Table 6:  Ion ratio precision in Bovine kidney over 3 validation days (n=35 for each day). The coefficient of 































DAY 1 0.26 0.12 3.33 2.52 25 30 0.999 
DAY 2 0.26 0.12 4.34 3.34 25 30 0.989 
DAY 3 0.25 0.12 4.89 2.68 25 30 0.973 
Table 7: Precision and accuracy results for each validation level in bovine kidney (n=7 on each of 3 days at each 





Figure 1:  A mixed solvent standard injection at 100ng/ml (equivalent to 100 µg kg-1 in tissue) showing the separation 
of FF and FFA.  The y-axis indicates % normalised relative intensity of total ion counts (TIC) for the MRM ion 
channels monitored.  The column void volume is indicated at 0.28min.  Trace A - TIC trace of FFA with a retention 
time of 1.09min; Trace B - TIC trace of FF with a retention time of 1.64min.   
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Figure 2: Stability of FFA in 6N HCl. FFA solvent standards were prepared at 100ng/ml and subjected to hydrolysis 
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Figure 3: Post column infusion of FFA at 100ng/ml with injections on column of a solvent blank and negative extracts 
of porcine kidney or muscle, and bovine kidney or muscle.  The y axis indicates the % relative baseline response for 
the quantification MRM channel 248>230 for FFA.   (A) Without a dispersive C18 step   (B) With dispersive C18 
clean-up.  An overlay of a 100ng/ml FFA standard injected on column (without post column infusion) is shown at a 
retention time of 1.09min. 
 
 
Figure 4:  Representative MRM ion chromatograms for FFA in porcine kidney samples: (A) Negative tissue control, 
(B) Kidney sample fortified at 300 µg kg-1 FFA tissue equivalents and (C) incurred porcine kidney tissue sample at 
1224 µg kg-1.  The y-axis has been normalised to the maximum MRM ion count intensity 
 
 
Figure 5:  Linearity and residual plots of florfenicol amine (FFA) in matrix standards prepared in bovine kidney.  
Matrix standards were spiked with florfenicol prior to the hydrolysis procedure (as FFA equivalents) to cover a 
concentration range of 50-1000 µg kg-1 
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